Testing a light-activated therapy in peripheral lung tumors
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1 trial tests padeliporfin, a light-activated medicine, delivered to lung tumors using robotic bronchoscopy. It may help people with small, peripheral lung cancer lesions by targeting the tumor without open surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a lung lesion that needs biopsy, and it must be confirmed as cancer during the study screening procedure
- Your tumor is small (about 2 cm or less for part A, or under 3 cm for part B) and you can have it treated by bronchoscopy
- The tumor is not too close to the center airways and not too close to the lung lining (pleura/fissures)
- You must be well enough for bronchoscopy under general anesthesia (heart/lung status must meet safety limits)
- You can’t be pregnant, and you must not currently be receiving other study treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a new cancer treatment called padeliporfin given through a special catheter to treat pancreatic ductal adenocarcinoma that cannot be removed by surgery. It aims to see how safe the treatment is and whether it can help control the tumor in people who are not surgical candidates.
This trial tests a new light-activated therapy (interstitial photodynamic therapy) after palliative radiation to shrink inoperable airway tumors and improve breathing. It is for people with solid cancers that block the airway from the outside and cannot be removed with surgery.
This trial tests a new light-based therapy (photodynamic therapy or PDT) using a drug called 5-ALA to treat advanced lung tumors. The treatment is delivered through a thin tube inserted into the lung (bronchoscopy), aiming to shrink tumors that can't be removed with surgery and haven't responded to other treatments.
This trial tests a new way to choose the best treatment for your lung cancer by creating a model of your tumor in the lab. It may help doctors find the most effective therapy for you.
This trial tests a new drug (ES102) combined with an immunotherapy (Toripalimab) for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help those whose tumors have high PD-L1 levels.
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Hear when a new Peripheral Lung Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.